Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

<p><strong>Background:</strong> Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their antiviral activities in patients have not been compared directly. The aim of this ongoing platform trial is to compare different antivir...

ver descrição completa

Detalhes bibliográficos
Principais autores: Schilling, WHK, Jittamala, P, Watson, JA, Boyd, S, Luvira, V, Siripoon, T, Ngamprasertchai, T, Batty, EM, Cruz, C, Callery, JJ, Singh, S, Saroj, M, Kruabkontho, V, Ngernseng, T, Tanglakmankhong, N, Tubprasert, J, Abdad, MY, Madmanee, W, Kouhathong, J, Suwannasin, K, Pagornrat, W, Piaraksa, N, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Poovorawan, K, Potaporn, M, Srisubat, A, Loharjun, B, Taylor, WRJ, Chotivanich, V, Chotivanich, K, Imwong, M, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ
Outros Autores: PLATCOV Collaborative Group
Formato: Journal article
Idioma:English
Publicado em: Elsevier 2023

Registros relacionados